Figure 5.
![Schematic overview of [13C6]glucose stable isotope tracings. (A) Tracing using [13C6]glucose including glycolytic and HMS pathways. (B) Tracing using [13C6]glucose in control and patient neutrophils before (time 0) and 5 minutes after incubation with 1 µM fMLF. Isotopologue intensities plotted correspond to labeling indicated in panel A (eg, 13C6 for glucose).](https://ash.silverchair-cdn.com/ash/content_public/journal/bloodadvances/4/23/10.1182_bloodadvances.2020002225/3/advancesadv2020002225f5.png?Expires=1735811064&Signature=p77pHyNuUYYfgowmWYJ13iIeULO7~dD0ToQpRpAdVc1wtL216Uo4hwzuTdq5l1fl1m-dqXFFhqESodTTfH1Gp2Lw5In2XOT0kuGP~cWrWCy9N25kdOxvQdTIroqNtCGS4cxRgaDaK6XtW53YFDPaGBuK15QxVDNtN3cgro7xfBIjf0AujXCnnCzSaWHWE6B069JR3zH-kxPSqqhMpDB2VjygrBlnL3ePEs-f0gmIIVKOokhxbmMtmv0Hl6tfL-mVcuXSoa8rT6to7Qb5VLPvTaIulu2Bg~-xM4fhTuTvFeijFX84d8g6QN4oUDnnYLKnLGOxtTNK1G3S0P3kDTN04Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Schematic overview of [13C6]glucose stable isotope tracings. (A) Tracing using [13C6]glucose including glycolytic and HMS pathways. (B) Tracing using [13C6]glucose in control and patient neutrophils before (time 0) and 5 minutes after incubation with 1 µM fMLF. Isotopologue intensities plotted correspond to labeling indicated in panel A (eg, 13C6 for glucose).